Basic information Safety Supplier Related

BML-210

Basic information Safety Supplier Related

BML-210 Basic information

Product Name:
BML-210
Synonyms:
  • N-PHENYL-N'-(2-AMINOPHENYL)HEXAMETHYLENEDIAMIDE
  • N-(2-AMINOPHENYL)-N'-PHENYL-OCTANEDIAMIDE
  • BML-210
  • CAY10433
  • N1-(2-aminophenyl)-N8-phenyl-octanediamide
  • BML-210(CAY10433)
  • BML-210, (BML210
  • CS-2301
CAS:
537034-17-6
MF:
C20H25N3O2
MW:
339.43
Mol File:
537034-17-6.mol
More
Less

BML-210 Chemical Properties

storage temp. 
2-8°C
solubility 
DMSO: >20mg/mL
form 
powder
color 
white to very faintly yellow
Stability:
Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 3 months.
More
Less

Safety Information

WGK Germany 
3
More
Less

BML-210 Usage And Synthesis

Description

Inhibition of histone deacetylase (HDAC) enzymes by compounds such as trichostatin A can have wide ranging effects in cancer, cell differentiation, and other aspects of gene expression regulation. BML-210 is a small molecule inhibitor of HDAC with an IC50 value of 30 μM when tested in HeLa cell nuclear extracts using 200 μM acetylated fluorometric substrate (substrate available in Cayman’s HDAC Activity and Inhibitor Screening Assay Kits - Item Nos. 10011563 and 10011564).

Uses

N1-(2-Aminophenyl)-N8-phenyloctanediamide is a histone deacetylase (HDAC) inhibitor, an anti-cancer target for breast cancer therapeutic intervention.

Definition

ChEBI: A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and 1,2-diaminobenzene.

Biochem/physiol Actions

BML-210 is a synthetic benzamide and is a potential tumor inhibitor. It is used as a therapeutic agent to treat promyelocytic leukemia. In human leukemia cell lines (NB4, HL-60, THP-1, and K562), BML-210 modulates histone deacetylase and promotes apoptosis. BML-210 favors frataxin expression in neurodegenerative disease Friedreich′s ataxia (FRDA). It interacts with myocyte enhancer factor-2 (MEF2) via hydrogen-bonding and prevents histone deacetylase 4 (HDAC4) binding.

References

1) Savickiene, et al. (2006), The novel histone deacetylase inhibitor BML-210 exerts growth inhibitory, proapoptotic and differentiation stimulating effects on the human leukemia cell lines; Eur. J. Pharmacol. 549 9 2) Herman, et al. (2006), Histone deacetylase inhibitors reverse gene silencing in Friedreich’s ataxia; Nat. Chem. Biol. 10 551

BML-210Supplier

Shanghai Boyle Chemical Co., Ltd.
Tel
Email
sales@boylechem.com
Haoyuan Chemexpress Co., Ltd.
Tel
021-58950125
Email
info@chemexpress.com
MedChemexpress LLC
Tel
021-58955995
Email
sales@medchemexpress.cn
AdooQ Bioscience CHINA
Tel
025-58849295 18951903616;
Email
info@adooq.cn
Shanghai JiYi Biotechnology Co. Ltd.
Tel
13621943973
Email
sales@shjiyipharmatech.com